Triple Negative Breast Cancer News and Research

RSS

30-year-old cancer drug could get another shot, study says

A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer, which is the most aggressive form of breast cancer and has few targeted therapies.

9 Feb 2022

Eikonoklastes completes a license to add novel gene therapy for treating neurodegenerative diseases

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced it has completed a license with the University of California San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases.

20 Jan 2022

MAPK4 may play a key role in triple-negative breast cancer

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.

12 Jan 2022

New combined therapy shows promising results in treating triple negative breast cancer

A drug used to treat cardiac failure has shown promising results in treating triple negative breast cancer, according to Houston Methodist researchers who released results this week on a new combined therapy with the potential to improve outcomes for these hard-to-treat breast cancer patients.

15 Dec 2021

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center.

2 Nov 2021

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.

17 Aug 2021

BioCurate’s new “Proof of Concept” funding to help accelerate research into targeted cancer therapies

The first award under BioCurate’s new “Proof of Concept” fund has been granted to the Monash Biomedicine Discovery Institute.

4 Aug 2021

Study finds a significant link between statins and survival rates of triple-negative breast cancer patients

A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.

3 Aug 2021

New insights on replication-stress sensitivity in breast cancer cells

Oncotarget published "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity" which reported that these authors recently documented that gain-of-function mutant p53 R273H in triple negative breast cancer cells interacts with replicating DNA and PARP1.

28 Jul 2021

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

27 Jul 2021

UTHSC researchers publish new findings on how obesity impacts cancer treatments

Liza Makowski, PhD, professor in the Department of Medicine and the UTHSC Center for Cancer Research, has long been interested in how the immune system is altered by obesity and how this impacts cancer risk and treatment.

25 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

18 Jun 2021

Triple Negative Breast Cancer News and Research

30-year-old cancer drug could get another shot, study says

Eikonoklastes completes a license to add novel gene therapy for treating neurodegenerative diseases

MAPK4 may play a key role in triple-negative breast cancer

New combined therapy shows promising results in treating triple negative breast cancer

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

BioCurate’s new “Proof of Concept” funding to help accelerate research into targeted cancer therapies

Study finds a significant link between statins and survival rates of triple-negative breast cancer patients

New insights on replication-stress sensitivity in breast cancer cells

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

UTHSC researchers publish new findings on how obesity impacts cancer treatments

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

Major anti-cancer protein released by neutrophils selectively kills tumor cells

New class of anti-cancer compounds effectively kills liver and breast cancer cells

Menopausal symptoms in breast cancer patients could be reduced through CBT delivered by nurses

Prolactin hormone acts as a major contributor to breast cancer development, studies find

Targeted therapy may be of great benefit in early stage breast cancer

Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials

Compound isolated from Moroccan fungus shows promise to fight triple negative breast cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News